R5 News
Meet R5 in Paris (CPhI/ICSE) and New Orleans (AAPS)
R5 will be exhibiting at the major pharmaceutical trade shows.
Paris Oct 5 – 7 (CPhi/ICSE) ... Read More
R5 - Management Team of the year finalist.
The British Venture Capital Association National awards final will be held at One Mayfair , London S... Read More
Aesica Pharmaceuticals aquires R5
Aesica Pharmaceuticals has today announced that it has successfully acquired leading research and de... Read More
R5 and Lena Nanoceutics undertake joint commercial development of novel milling technology
R5 Pharmaceuticals Ltd and Lena Nanoceutics Ltd have today agreed to jointly develop the market for ... Read More
R5 Pharmaceuticals Ltd.
R5 develops and manufactures new medicines and clinical trial materials for Phase 1 and Phase 2 clinical trials. R5 is a subsidiary of Aesica Pharmaceuticals Ltd. Projects include most dosage forms and all are produced at R5's GMP labs.
R5 is licensed by MHRA for the GMP manufacture and testing of Investigational Medical Products (IMPs) and Specials.
 |
 |
 |
 |
 |